NeutriSci Announces a Major R&D MOU With Scientus Pharma to Develop a Medical Cannabinoid Retail Product

VANCOUVER, British Columbia, Jan. 08, 2018 (GLOBE NEWSWIRE) -- NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V:NU) (OTCQB:NRXCF) (FRANKFURT:1N9), the innovator and pioneer behind neuenergy®, is pleased to announce it has entered into a major R&D Memorandum of Understanding with Scientus Pharma Inc. ("Scientus Pharma"). Under the terms of the MOU, both companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for existing retail distribution networks across Canada.

The core ingredients in NeutriSci’s products have significant anti-oxidant properties and health benefits. Scientus Pharma will conduct research on NeutriSci’s products and their components in combination with various cannabinoids. Research activities will initially be funded by NeutriSci. Both companies will have rights for further product development and testing, including potentially preclinical and clinical trials, which may be co-funded.

NeutriSci President Mr. Glen Rehman stated, "This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant player in the cannabis space in Canada. Through a collaborative effort, we will incorporate NeutriSci’s IP, technology and ingredients with Scientus’ expertise, proprietary technical know-how, and resources. By leveraging both parties existing partnerships, we will be positioned to offer the national retail consumer a safe, effective, dose controlled product that completes our ‘plant to blood stream’ strategy.”

“NeutriSci brings a wealth of retail distribution and consumer branding expertise,” said Scientus Chairman Mr. Har Grover. “They have had success innovating with neuenergy and the brand has good presence in several health and wellness settings. Pterostilbene and related compounds present interesting targets for further research and we are looking forward to this collaboration.”

About Scientus Pharma
Hydrx Farms Ltd. O/A Scientus Pharma is a vertically-integrated biopharmaceutical Licensed Dealer under the Narcotics Control Regulations promulgated under the Controlled Drugs and Substances Act (Canada) with a focus on developing and commercializing pharmaceutical-grade medicinal cannabinoid derivative products. Being one of a limited number of Licensed Dealers in Canada authorized to handle cannabinoid products, Scientus Pharma has the ability to wholesale, buy, process and sell cannabinoid derivatives from and to Licensed Producers, as well as international markets. The company recently received its Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license from Health Canada.

About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci is currently focussed on increasing the size of its existing national retail network in Canada by building sustainable sales models with Convenience, Chain Drug, Mass Market and Supermarket retailers for neuenergy® and new novel ingredients for product distribution. It also continues to develop emerging sales channels in the US, Europe and Asia.

On Behalf of the Board of Directors of

Glen Rehman
CEO & President
Tel: (403) 264-6320

Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration.  Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.